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Inherited arrhythmias, such as cardiomyopathies and cardiac ion channelopathies, along with coronary
heart disease (CHD) are three most common disorders that predispose adults to sudden cardiac death. In
the last three decades, causal genes in inherited arrhythmias have been successfully identiﬁed. At the
same time, it has become evident that the genetic architectures are more complex than previously
known. Recent advancements in DNA sequencing technology (next generation sequencing) have enabled
us to study such complex genetic traits.
This article discusses indications for genetic testing of patients with inherited arrhythmias. Further, it
describes the beneﬁts and challenges that we face in the era of next generation sequencing. Finally, it
brieﬂy discusses genetic counseling, in which a multidisciplinary approach is required due to the
increased complexity of the genetic information related to inherited arrhythmias.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
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Sudden cardiac death (SCD) is a tragic event and the aftermath
is devastating to the surviving family and community. SCD occurs
in nearly 400,000 cases every year in the US [1]. In adult popu-
lations, cardiomyopathies and cardiac ion channelopathies, along
with coronary heart disease (CHD), are the most common condi-
tions that predispose patients to SCD. According to recent epide-
miological studies of SCD in Western countries, CHD, cardiomyo-
pathies, and ion channelopathies are diagnosed in 75%, 10–15%,
and 1–2% of the SCD cases, respectively [2]. In Japan, approxi-
mately 50,000 new cases of SCD are diagnosed every year [3]. CHD
is less common in Japan than in Western countries: CHD, cardio-
myopathies, and ion channelopathies account for 50–60%, 30–35%
and 10% of the SCD cases, respectively [2]. In children or adults
younger than 35 years of age, cardiomyopathies and ion channe-
lopathies account for signiﬁcant proportions of SCD [4]. Because of
the low survival rate in aborted SCD cases (r10%) [2], identiﬁ-
cation of patients at risk of arrhythmia is very important for the
prevention of SCD.
Inherited arrhythmia-susceptibility genes have been success-
fully identiﬁed in the last three decades. This has broadened both
our understanding of the mechanisms and the clinical manage-
ment of inherited arrhythmias. At the same time, it has become
evident that the genetic architectures of inherited arrhythmias are
actually more complex than previously known, involving more
genetic components than a single gene locus. A recent advance in
sequencing technology (next generation sequencing [NGS]) has
facilitated the search for such genetic components spread over the
genome.
This article provides a concise overview of genetic testing for
inherited arrhythmias used in current clinical practice. It also
provides a short introduction to NGS technology. Further, it brieﬂy
discusses genetic counseling, in which a multidisciplinary
approach is required due to the increased complexity of genetic
information regarding inherited arrhythmias. Because this article
aims to provide basic knowledge regarding inherited arrhythmias
for readers who are unfamiliar with this ﬁeld, more detailed
clinical and genetic characteristics of inherited arrhythmias are not
within the scope of this article and can be found elsewhere [5–11].Table 1
Major genes associated with inherited arrhythmias.
Disease Genes (yield, %)
Long QT syndrome KCNQ1 (30–35), KCNH2 (25–30),
SCN5A (5–10) [25]
Catecholaminergic Polymorphic Ventricular
Tachycardia
RYR2 (60–65),CASQ2 (o5)
[47,49]
Brugada Syndrome SCN5A (20) [60]
Hypertrophic cardiomyopathy MYBPC3 (30–40), MYH7 (20–30),
TNNT2 (10), TNNI3 (7) [66]
Dilated cardiomyopathy TTN (25) [80]
Arrhythmogenic right ventricular dysplasia/
cardiomyopathy
PKP2 (46), PLN (5) [62]2. Genetic testing for inherited arrhythmias
2.1. Classic genetic testing: candidate gene approach
Disease-causing genes for inherited arrhythmias have been
successfully identiﬁed in the last three decades, resulting in a large
impact on patient care. This success has largely been through the
use of classical linkage mapping. Linkage mapping is performed in
affected family members, followed by candidate gene sequencing
within an identiﬁed disease susceptibility locus. Such analysis was
performed with the assumption that inherited arrhythmias are
Mendelian (monogenic) disorders and that a single mutation
contributes substantially to the risk. In Table 1, the most com-
monly identiﬁed genes in inherited arrhythmias are shown.
Presently, genetic testing for causal genes in a proband is used
to conﬁrm diagnosis. Genetic testing can also be used to performcascade screening (mutation-speciﬁc testing) in family members
of genotype-positive probands to exclude a diagnosis (in the case
of a negative test) or to allow targeted testing (in the case of a
positive test) [11]. Diagnostic, therapeutic, and prognostic values of
genetic testing are most relevant in long QT syndrome (LQTS)
wherein genotype–phenotype correlation (i.e. the association
between a certain mutation [genotype] and clinical characteristics
[phenotypes]) is robust. In catecholaminergic polymorphic ven-
tricular tachycardia (CPVT), genetic testing plays an important role
in diagnosis. The clinical utility of genetic testing is limited in the
remaining inherited arrhythmias [11], because of as yet unknown
genotype–phenotype correlation or because of the low yield of
genetic testing (Fig. 1).
Genotype–phenotype correlation is complicated when some
phenotypes, such as electrocardiographic abnormalities and
arrhythmias, do not manifest in all individuals carrying the same
gene mutation (incomplete penetrance), and when the type and
severity of the phenotypes vary between genotype-positive indi-
viduals (variable expressivity) [12]. For example, in families with
Brugada syndrome (BrS) that carry the familial SCN5A mutation,
not all affected family members (mutation carriers) show diag-
nostic type 1 BrS ECG or other symptoms [13]. Such puzzling
phenomena are the focus of ongoing genetic research. Meanwhile,
consensus reports provide recommendations to guide clinicians in
the appropriate use of genetic testing for inherited arrhythmias
[11]. It is important to keep in mind that in any inherited
arrhythmia, clinical examinations are critical for accurate diagnosis
before genetic testing is implemented.
2.2. New sequencing technology: next generation sequencing (NGS)
As suggested by the incomplete penetrance and variable
expressivity seen in mutant genotypes, the genetic architecture of
inherited arrhythmias is more complex than initially thought. It is
hypothesized that in addition to a mutation in a single disease-
susceptibility gene, as seen in pathogenic variants found in o1% of
the general population, other genetic (and environmental) factors
are involved in the ultimate manifestation of inherited arrhyth-
mias [10]. In recent years, it became possible, using NGS technol-
ogy, to screen for such common or rare variants (frequency in the
general population 41–5% and o1%, respectively) [14]. These
variants have a smaller impact on disease risk than mutations, but
have an aggregated inﬂuence on disease manifestation.
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massive scale across the genome to ﬁnd additional genetic loci
involved in a disease. In the last decade, genome wide associa-
tion studies (GWAS) were conducted to identify common single
nucleotide polymorphisms (SNPs) associated with SCD or ECG
parameters, because SCD/ECG parameters were shown to have
heritable components [14]. With regard to rare inherited
arrhythmias, Bezzina et al. was the ﬁrst to report an association
between common SNPs and BrS [15]. These exciting ﬁndings using
GWAS pave the way for functional analyses and for better under-
standing of the mechanisms of inherited arrhythmias.
NGS is used in gene panels to sequence multiple genes simulta-
neously (e.g. 20–80 comprehensive arrhythmia or cardiomyopathy-
associated genes) or to sequence whole exomes/genomes in order to
ﬁnd variants with intermediate to large effect sizes on phenotypes
[14]. In the last couple of years, the successful application of NGS
for the discovery of rare variants in heritable arrhythmia syndromes
has been reported. Intriguing examples are cases of early onset and
recurrent episodes of ventricular ﬁbrillation (VF) without identiﬁcation
of pathogenic mutationwhen using classical genetic testing [16,17]. VF
was refractory to all medical treatments in these cases. Furthermore,
clinical or familial history did not provide clues for effective therapy,
except for the use of an implantable cardioverter deﬁbrillator [ICD].
Whole exome sequencing (WES) was performed in symptomatic
siblings [16] or in parents and a child (parent–child trios) [17], which
led to discovery of mutations in the calmodulin genes. As just
described, WES is becoming a promising approach to uncover
pathogenic variants associated with heritable conditions.
NGS is not a perfect tool, but is a developing method to uncover
new variants/mutations that may be involved in disease condi-
tions. The technique is expected to allow improved diagnosis,
better prognostic evaluation, or enhanced individual therapy.
However, we are currently facing an increased number of rare
variants of uncertain signiﬁcance (VUS), that is, variants whose
association with disease risk is unknown, as a result of massive
sequence data. To conﬁrm pathogenicity in VUS, a number of cri-
teria need to be carefully evaluated by experts in the ﬁeld, such as
geneticists, cardiologists, and genetic counselors, to allow the
ﬁndings to be interpreted in the context of clinical practice. These
criteria include cosegregation of the unraveled variant with dis-
ease, absence or extreme rarity of the variant in control cohorts,
types of mutation (missense mutation vs. nonsense, frameshift,
insertion/deletion mutations that lead to truncated protein pro-
ducts), and results of functional studies.Fig. 1. Diagnostic yields of genetic testing in inherited arrhythmias. Diagnostic
yields are variable among cardiomyopathies and channelopathies. Data shown was
taken from [11].3. Inherited arrhythmias with structurally normal hearts:
cardiac ion channelopathies
Cardiac ion channelopathies, such as LQTS, CPVT and BrS, are
heritable conditions with an increased risk of SCD in otherwise
normal hearts. An ion channelopathy manifests when ion channel
function is disrupted by a mutation in a gene encoding a cardiac
ion channel or an ion channel-related protein. Clinical and genetic
characteristics of each condition are described below.
3.1. Long QT syndrome (LQTS)
Congenital LQTS is characterized by a prolonged QT interval
(Fig. 2) and syncope/VF secondary to peculiar polymorphic ven-
tricular tachycardia, called torsades de pointes (TdP). The pre-
valence of LQTS is estimated to be as high as 1 in 2000 [18].
The ﬁrst cardiac event occurs in teenagers (1379, 18710, and
16710 years in LQT1, LQT2, and LQT3, respectively) [19]. Syncope
is the most common, ﬁrst symptom, while aborted sudden cardiac
arrest (ACA)/SCD is rare (1–3%) [20]. The mainstay of LQTS diag-
nostics is the evaluation of clinical characteristics, including
symptoms, family history and electrocardiographic ﬁndings, using
the diagnostic scoring system (Schwartz score) [21]. When the
diagnosis is established, beta-blockers are introduced as the ﬁrst-
line of therapy. ICD is indicated in aborted SCD cases [22,23].
3.1.1. Genetic testing in LQTS
LQTS segregates in a Mendelian fashion; in the majority of
cases of LQTS, it is transmitted in an autosomal dominant pattern
(Romano–Ward syndrome), and in the minority of cases, in an
autosomal recessive pattern (Jervell and Lange–Nielsen syndrome)
[11]. To date, mutations in 15 different genes have been implicated
in LQTS [5]. A causal mutation is found in approximately 75% of
LQTS patients with a Schwartz score Z4 [24]. The KCNQ1 gene,
encoding the Kv7.1 potassium channel (LQT1, 30–35%), the KCNH2
gene, encoding theKv11.1 potassium channel (LQT2, 25–30%),
and the SCN5A gene, encoding the Nav1.5 sodium channel (LQT3,Fig. 2. ECG in a patient with LQTS type 2. Baseline ECG of a patient with LQTS type
2 is shown. QTc interval was prolonged and abnormal T waves (negative in V1–V3)
were observed (HR 71 bpm, QTc 480 ms). LQTS¼ long QT syndrome; QTc¼cor-
rected QT interval (Bazett's formula).
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LQTS (Table 1) [25]. Testing the remaining minor LQTS-associated
genes increases the diagnostic yield by only o5%, while it also
increases the chance of encountering a false-positive result [26].
Therefore, comprehensive screening of LQTS genes is not currently
a common practice.
Because genotype–phenotype correlation is robust in the major
LQTS subtypes (LQT1–LQT3), genotype can be inferred by thor-
ough clinical evaluation. For example, in LQT1, cardiac events
occur during physical exertion or emotional stress, typically during
swimming [27]. Auditorial stimulation, such as an alarm clock or a
telephone bell, is a typical trigger for ventricular arrhythmia (VA)
in LQT2 [28]. In LQT3, symptoms are generally observed during
rest or at night [27,29]. T wave morphology may also help to
distinguish different LQTS subtypes (LQT1 [broad T wave], LQT2
[biphasic T wave] and LQT3 [late-appearing T wave]) [30].
As for clinical symptoms of minor LQTS subtypes, severe phe-
notypes, such as longer QTc or early onset of arrhythmic events
[31,32], suggest the presence of compound mutations in
approximately 10% of the genotype-positive patients [33]. The
presence of extracardiac phenotypes point to two rare subtypes:
LQT7 (Andersen–Tawil syndrome) and LQT8 (Timothy syndrome).
LQT7 is caused by mutations in the KCNJ2 gene, which results in
loss-of-function of the inward rectifying potassium channel Kir2.1
[34], and may manifest periodic paralysis and dysmorphic features
as extracardiac symptoms. LQT8 is an extremely rare and highly
malignant form of LQTS, carrying mutations in the CACNA1c gene
[35–38]. Typical extracardiac manifestations are dysmorphic facial
features, immune deﬁciency, developmental delay, and syndac-
tyly; however, not all LQT8 patients develop these extracardiac
symptoms [35–38].
Prognosis of LQTS is inﬂuenced by the location and type of
mutation. In LQT1, missense mutations and transmembrane
mutations cause a longer QT interval and an increased risk of
cardiac events [39]. In LQT2, the risk of SCD is higher in females
than in males. Among LQT2 females, the risk of SCD is not sig-
niﬁcantly different between patients with and without pore–loop
mutations [40]. Among LQT2 males, patients with pore–loop
mutations [40] and missense mutations [41] showed higher
chances of SCD than patients with non-pore–loop mutations.Fig. 3. Exercise stress testing of CPVT. Baseline ECG (A) and an ECG during exercise stress
VES and NSVT. CPVT¼catecholaminergic polymorphic ventricular tachycardia; NSVT¼nIn LQTS therapeutics, genotypes are particularly helpful in
predicting the efﬁcacy of therapy using beta-blockers. For the LQTS
subtypes LQT1–LQT3, therapy using beta-blockers is extremely
effective for patients with LQT1 but less protective for those with
LQT2 and LQT3 [42]. In patients with LQT3, mexiletine may be
used in addition to beta-blockers because it shortens QTc by
blocking sodium channel currents [43]. However, caution is war-
ranted when using mexiletine to treat LQT3 patients because its
effect is dependent on the type of mutation; it can be beneﬁcial in
some LQT3 patients, but harmful in others [44,45].3.2. Catecholaminergic polymorphic ventricular tachycardia (CPVT)
CPVT is characterized by polymorphic ventricular tachycardia
(bidirectional VT) triggered by adrenergic stimulation, such as
exercise or emotional stress. The prevalence of CPVT in the general
population is estimated to be 1:10,000 [7]. Patients are typically
admitted to a hospital with syncopal episodes caused by poly-
morphic VT, which may degenerate to VF and SCD. Cardiac
examinations reveal no structural abnormality in the heart and
normal baseline ECG. Therefore, establishing patient history, such
as symptoms after physical/emotional stress, family history of SCD,
is important in the diagnosis of CPVT. Exercise testing is the gold
standard for diagnosis: during an exercise test, ventricular pre-
mature beats and non-sustained VT are reproducibly induced
(Fig. 3). The mean age for the onset of symptoms is 8 years.
Approximately 30% of patients with CPVT develop symptoms
before 10 years of age, and 60% before 40 years [11].
Beta-blockers, combined with exercise restriction, are the ﬁrst-
line of therapy for CPVT. Among several beta-blockers, Nadolol, a
long-acting, non-selective beta-blocker, seems to be more effective
than others [46]. When patients are under treatment with beta-
blockers, fatal/near-fatal events at 4 year- and 8 year-follow up
occur in 1–7% and 11–14% of the patients, respectively [7], mostly
because of poor drug compliance. Therefore, it is crucial to inform
CVPT patients about the potential fatal consequences of non-
compliance to medication. For those refractory to beta-blockers,
ﬂecainide, in addition to the beta-blockers, seems effective [7].testing (B) in a patient with CPVT are shown. The ECG during exercise testing shows
on-sustained ventricular tachycardia; VES¼ventricular extra systoles.
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In CPVT, 60–65% of the patients carry a mutation in the RYR2
gene, which is transmitted in an autosomal dominant pattern,
whereas, a mutation in the CASQ2 gene, which is transmitted in an
autosomal recessive pattern, is found in only small percentage of
index cases (Table 1) [47–49]. Mutations in these genes trigger
arrhythmias as a result of increased calcium release from the
sarcoplasmic reticulum. Rarely, CPVT is diagnosed with mutations
in the calmodulin genes, CALM1 [50] and CALM2 [51]. A CPVT
phenotype also develops in Andersen–Tawil syndrome (LQT7),
which is caused by mutations in the KCNJ2 gene [52]. Thus, it is
particularly relevant for RYR2/CASQ2 mutation-negative patients
to consider being screened for mutations in these genes [52].
Because SCD can be the ﬁrst manifestation of CPVT, genetic
testing is clinically relevant, especially for the management of
family members. The most recent HRS/EHRA guidelines recom-
mend screening for CPVT susceptibility genes in index cases with
clinically established/suspected CPVT, and cascade screening in
family members of index cases with a putative, pathogenic
mutation [11]. At present, there are no genotype-based risk stra-
tiﬁcation or therapeutic approaches in CPVT [11].
3.3. Brugada syndrome (BrS)
BrS is diagnosed by the presence of its characteristic ECG pat-
tern: type1 BrS ECG (Fig. 4). It is deﬁned as Z2 mm ST-segment
elevation with coved-type morphology in Z1 lead of the right
precordial leads (V1–V3 in 4th–2nd intercostal spaces) [23]. The
typical ECG pattern may manifest spontaneously, either after a
sodium channel blocker is administered during drug-challenge
testing or during fever, and it may ﬂuctuate over time. The pre-
valence of BrS is estimated to be 5:10,000 in the general popula-
tion [53].Fig. 4. ECG in a patient with BrS. Spontaneously appearing type 1 ECG was
observed in lead V2. BrS¼Brugada syndrome.In BrS, phenotypes are heterogeneous. Symptoms, such as VF or
syncope due to VA, typically occur at rest or during sleep in adults
that are in their 40s. Meanwhile, some individuals with diagnostic
ECG pattern remain asymptomatic for life. Therefore, it is critical to
accurately identify patients at risk, although the risk stratiﬁcation
in BrS is still ill deﬁned. As expected, patients with a history of VF
are at high risk for recurrent VF (approximately 8–10% of patients/
year) [54,55]. It is generally agreed that syncope in the presence of
spontaneous type 1 ECG identiﬁes high-risk patients [23]. The
outcome of asymptomatic cases are much more benign compared
to that in symptomatic cases, even in the presence of spontaneous
type 1 ECG (approximately 0.5–0.8% of patients/year) [54,55].
The only effective therapy for BrS is implantation of ICD.
However, because ICD implants have a high complication rate
(approximately 9% of patients/year) [56], ICD should be indicated
only in those with documented, or strongly suspected, VAs [23]. In
cases with repetitive VF attacks, isoproterenol infusion is effective
in acute settings to suppress VF [57]. In chronic settings, quinidine,
a Class Ia antiarrhythmic drug, is used as an adjunctive therapy to
treat recurrent VAs [58].
3.3.1. Genetic testing in BrS
BrS is transmitted in an autosomal dominant pattern. Loss
of function mutations in SCN5A, encoding the Nav1.5 sodium
channel, account for approximately 20% of BrS cases (Table 1) [59].
Other genes reported in BrS are found in o5% [60] of cases, and
the majority of BrS patients remain genetically elusive. Minor BrS-
associated genes include: sodium channel β-subunit genes (SCN1B,
SCN3B); Glycereol-3 phosphate dehydrogenase 1-like enzyme
(GPD1L); MOG1, which affects trafﬁcking of sodium channels;
calcium channel genes (CACNA1C, CACNB2b, CACNA2D1); and
genes that affect the Ito (KCNE3, KCND3), IK-ATP (KCNJ8), and the If
(HCN4) currents [6].
Thorough clinical evaluation, but not genetic testing, is the
standard for diagnosis of BrS. The recent HRS/EHRA consensus
guidelines recommend cascade screening in family members of
genotype-positive index cases [11]. Screening SCN5A can be useful
in clinically suspected BrS index cases. At present, genotype is not
relevant for prognostic or therapeutic measures [11].4. Inherited arrhythmias with structural abnormality:
cardiomyopathies
To date, thousands of variants have been associated with
inherited cardiomyopathies. A major challenge is to determine
whether these variants are truly pathogenic or benign poly-
morphisms. In relation to arrhythmogenic right ventricular dys-
plasia/cardiomyopathy (ARVD/C), a recent clinical study involving
a large number of patients has provided valuable information
regarding the genotype–phenotype correlation [61,62].
4.1. Hypertrophic cardiomyopathy (HCM)
HCM is deﬁned by the presence of increased left ventricular
wall thickness that is not solely explained by abnormal (pressure
or volume) loading conditions [63]. HCM includes both familial
and non-familial subtypes, regardless of the presence of extra-
cardiac traits. HCM is relatively common disease: its prevalence is
estimated to be approximately 1:500 in the general population
[64], which is similar among different ethnic groups [63]. HCM is
the most common cause of SCD in young, otherwise healthy
individuals [65]. Symptoms, such as heart failure (HF), may occur
in HCM patients due to diastolic dysfunction. A small proportion of
HCM patients eventually develop systolic dysfunction.
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HCM shows predominantly an autosomal dominant transmis-
sion with age-related penetrance, and 450% of HCM patients are
estimated to have familial disease [66]. HCM is known as a “dis-
ease of the sarcomere.” Approximately 60% of HCM cases harbor
mutations in sarcomere genes, which encode for components of
the contractile apparatus of the heart. Most mutations have been
identiﬁed in the β-myosin heavy chain gene, MYH7 (20–30%), and
in the cardiac myosin-binding protein C gene, MYBPC3, (30–40%).
Less frequent mutations have been identiﬁed in the cardiac tro-
ponin T gene, TNNT2 (10%), and in the cardiac troponin I gene,
TNNI3 (7%) (Table 1). Mutations in other sarcomere genes are rare.
In an Asian familial HCM cohort, the yield of MYBPC3 gene
mutations was less than in Western countries (MYH7 19%, MYBPC3
11%, TNNT2 12%, TNNI3 3%) [9].
Carriers of pathogenic mutations typically harbor a single muta-
tion. Five to seven percent of cases carry Z2 mutations. These can be
compound heterozygous mutations, which are heterozygous muta-
tions in each allele of the same gene, digenic heterozygous mutations,
which are heterozygous mutations in two different genes, or homo-
zygous mutations [66]. In rare cases, left ventricular hypertrophy may
be caused by non-sarcomeric gene mutations. For example, in 25%
of children with HCM, metabolic disease (e.g. Pompe disease), mal-
formation syndromes (e.g. Noonan syndrome), and neuromuscular
disorders (e.g. Friedreich ataxia) are diagnosed [67]. In adults, non-
sarcomeric gene mutations are rarely observed, but can include Fabry
disease, Danon disease, familial amyloidosis, or mitochondrial cardi-
omyopathies [66].
Based on the 2014 ESC guidelines for HCM, genetic testing is
recommended in deﬁnite HCM index cases (a wall thickness
Z15 mm in one or more LV myocardial segments measured by
any imaging modality) and in family members of genotype-
positive index cases [63]. Genetic testing for clinical manage-
ment, including diagnosis, risk stratiﬁcation, and therapy, is cur-
rently of limited value [63].Fig. 5. ECG in a patient with ARVD/C. Epsilon waves and inverted T waves (V1–V6)
were detected. ARVD/C¼arrhythmogenic right ventricular dysplasia/cardiomyopathy.4.2. Dilated cardiomyopathy (DCM)
DCM is characterized by left ventricular enlargement and sys-
tolic dysfunction with a prevalence of 1:2500 in the general
population [68,69]. Clinical manifestations include HF, throm-
boembolism, and SCD. Most patients are diagnosed with DCM
between the ages of 20 and 50 [70]. While different causes may
lead to DCM, 20–50% of DCM cases are estimated to carry a genetic
component based on the presence of family history [11]. These
patients are often referred as ‘idiopathic’ or ‘inherited’ DCM.
4.2.1. Genetic testing in DCM
Inherited DCM is predominantly transmitted as an autosomal
dominant trait. In a minority of cases, X-linked, recessive, or
mitochondrial inheritance patterns occur [71]. To date, more than
40 genes that encode cytoskeletal, sarcomeric or Z-disk proteins
have been associated with DCM or DCM in combination with
early-onset conduction system disease. Mutations in ion channel
genes and desmosome genes have also been associated with DCM.
Variants associated with DCM are found most frequently in TTN
(up to 25%) [9,66]. Variants in other genes are rarely found.
Familial DCM is observed in 20–35% of cases when ﬁrst-degree
relatives are screened, underscoring the need for cascade screen-
ing in family members. Currently, no prognostic or therapeutic
implications of genetic testing exist in DCM except for LMNA and
DES variants, which carry an increased risk of SCD [11].4.3. Arrhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C)
ARVD/C is a heritable cardiomyopathy characterized by ﬁbro-
fatty replacement in the right ventricle. The prevalence in the
general population is 1:5000 [8]. Patients typically present with
arrhythmia-related symptoms, including palpitations, syncope, or
SCD, between the ages of 20 and 59 years [62]. ECG of a patient
with ARVD/C is shown in Fig. 5. A recent cohort study reported
that in 439 unrelated probands with ARVD/C who fulﬁlled the
2010 diagnostic task force criteria [72], sustained VA including
aborted SCD was the 1st symptom in 61% of the cases [62]. At a
median of 7 years follow-up, 72% developed sustained VA.
Appropriate risk stratiﬁcation, including indication for ICD [73],
led to a good prognosis, which included cardiac mortality in 7%
[62]. HF manifests less commonly and usually develops at a
later stage.
4.3.1. Genetic testing in ARVD/C
ARVD/C is inherited predominantly as an autosomal dominant
trait, although it is also transmitted as an autosomal recessive trait
(Naxos disease or Carvajal syndrome) in a minority of cases [74]. It
is widely considered to be a desmosomal disease. Desmosomes are
one of the junctional complexes at the intercalated disk that are
essential for structural and functional integrity of cardiac tissue.
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ponents and to the development of structural abnormalities typi-
cal of ARVD/C. Mutations in ﬁve desmosomal genes, including
junction plakoglobin [JUP], DSP, PKP2, desmoglein-2 [DSG2], and
desmocollin-2 [DSC2], cause ARVD/C. More recently, the extra-
desmosomal genes transforming growth factor beta3 (TGFB3),
transmembrane protein 43 (TMEM43), desmin (DES), titin (TTN),
phospholamban (PLN), lamin A/C (LMNA), and αT-catenin
(CTNNA3) have been associated with atypical forms of ARVD/C
[75].
ARVD/C susceptibility gene mutations are found in approxi-
mately 60% of ARVD/C index cases, of which the majority are
desmosomal gene mutations (PKP2 [46%], PLN [5%], DSG2 [4%], DSP
[3%], and DSC2 [1%]) [62]. A recent large cohort study collected
from the Johns Hopkins and the Dutch ARVD/C registries [61]
reported that of 555 ARVD/C index patients and family members
who carry a pathogenic mutation, 80% carried a single PKP2
mutation. Other desmosomal gene mutations (JUP, DSG2, DSC2,
DSP) were found in 10% of the study population. Compound
mutations were found in 4%, which led to earlier onset of symp-
toms including VA and HF. Among single mutation carriers, pre-
mature truncating, splice site, and missense mutations were
identiﬁed in 60%, 23%, and 14%, respectively. However, outcomes,
including arrhythmic events, HF, and death, were not signiﬁcantly
different between different types of mutations. Among Asians,
PKP2 gene mutations were most commonly found (54%) in a
Chinese ARVD/C cohort consisting of 100 ARVD/C probands [76],
whereas, in a small series of ARVD/C in Japan (35 patients),
mutations in PKP2, DSP, and DSG2 were found in 28.6%, 20%, and
8.6%, respectively [77]. This implies diverse proportions of AVRD/C
causal genes among different ethnicities. Of note, pathogenicity of
an identiﬁed missense variant requires careful evaluation because
missense variants in ARVD/C susceptibility genes are commonly
found (16%) as background noise in the general population [78].
The ARVD/C Genetic Variants Database is currently available
online (http://www.arvcdatabase.info/), and summarizes ARVD/C-
associated variants and their pathogenesis [75].
While the 2010 diagnostic task force criteria include identiﬁ-
cation of a putative ARVD/C susceptibility gene mutation as a new
major diagnostic criterion [72], genetic testing should be used as a
conﬁrmatory tool for diagnosis of ARVD/C in index cases. Cascade
screening is recommended in family members [74]. A recent large
cohort study reported that carriers of mutations in desmoplakin
(DSP) are more likely to present with SCD and more prone to left
ventricular dysfunction and HF than carriers with mutations in
Plakophilin-2 (PKP2) [61]. Prognostic and therapeutic implications
of genetic testing in ARVD/C await further analyses of large-scale
clinical studies.5. Genetic counseling in inherited arrhythmias
Since genetic testing was implemented in clinical practice, the
importance of genetic counseling in probands as well as in family
members with inherited arrhythmias has been recognized. When
a patient is confronted with the risk of sudden death and a pos-
sibility of transmitting a potentially fatal disease to his/her chil-
dren, psychological consequences may naturally occur. Such psy-
chological distress can, in fact, be addressed and improved by pre-
and post-genetic test counseling [79]. A major problem currently
faced in the era of NGS is that rare VUS are increasingly identiﬁed
in disease-susceptibility genes, while there is no standard platform
that allows proper processing and integration of raw massive
genomic data with clinical data. Furthermore, NGS provides a
chance to incidentally uncover pathogenic mutations in other,
non-inherited arrhythmia-related conditions.It is of paramount importance to assemble a team of experts to
interpret the complex results of genetic testing. Therefore, a
multidisciplinary approach involving the cooperation of cardiolo-
gists, geneticists, genetic counselors, and psychologists, and the
interaction between experienced academic and local hospitals is
strongly recommended [11]. Meanwhile, in research settings, col-
laboration and data sharing between research groups is encour-
aged to advance our understanding of the intricate genetic archi-
tectures of inherited arrhythmias.6. Conclusions
Remarkable advances have been achieved in genetic testing of
inherited arrhythmias in the last three decades. Technological
advances in DNA sequencing have further increased the ability to
analyze complex architectures of inherited arrhythmias. Yet there
are many challenges to implementing NGS into clinical practice.
Ceaseless efforts to assemble massive genetic data and to build
standard platforms for integrating genetic data into clinical data
will further expand our understanding of inherited arrhythmias
and will improve patient care.Conﬂict of interest
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